HomeCompareSRDX vs EQR

SRDX vs EQR: Dividend Comparison 2026

SRDX yields 4.65% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $20.7K in total portfolio value
10 years
SRDX
SRDX
● Live price
4.65%
Share price
$42.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.1K
Annual income
$626.90
Full SRDX calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — SRDX vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSRDXEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SRDX + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SRDX pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SRDX
Annual income on $10K today (after 15% tax)
$395.53/yr
After 10yr DRIP, annual income (after tax)
$532.87/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $4,121.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SRDX + EQR for your $10,000?

SRDX: 50%EQR: 50%
100% EQR50/50100% SRDX
Portfolio after 10yr
$37.5K
Annual income
$3,051.25/yr
Blended yield
8.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

SRDX
Analyst Ratings
1
Strong
3
Buy
2
Hold
1
Sell
Consensus: Buy
Price Target
$39.50
-8.1% upside vs current
Range: $36.00 — $43.00
Altman Z
7.6
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SRDX buys
0
EQR buys
0
No recent congressional trades found for SRDX or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSRDXEQR
Forward yield4.65%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$27.1K$47.8K
Annual income after 10y$626.90$5,475.61
Total dividends collected$5.5K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$39.50$70.35

Year-by-year: SRDX vs EQR ($10,000, DRIP)

YearSRDX PortfolioSRDX Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$11,165$465.33$11,380$679.82$215.00EQR
2$12,432$485.57$13,014$837.25$582.00EQR
3$13,808$505.31$14,961$1,036.20$1.2KEQR
4$15,299$524.50$17,297$1,289.22$2.0KEQR
5$16,913$543.12$20,121$1,613.15$3.2KEQR
6$18,658$561.14$23,561$2,030.84$4.9KEQR
7$20,543$578.54$27,783$2,573.54$7.2KEQR
8$22,576$595.30$33,013$3,284.39$10.4KEQR
9$24,768$611.43$39,547$4,223.51$14.8KEQR
10$27,129$626.90$47,791$5,475.61$20.7KEQR

SRDX vs EQR: Complete Analysis 2026

SRDXStock

Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Full SRDX Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this SRDX vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SRDX vs SCHDSRDX vs JEPISRDX vs OSRDX vs KOSRDX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.